In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Institute for Regenerative Medicine

Division of Astellas Pharma Inc.
astellas.us/therapeutic/rnd/airm

Latest From Astellas Institute for Regenerative Medicine

Astellas Targets ALS In Expansion Of Cytokinetics Alliance

Astellas and Cytokinetics are expanding their existing alliance to investigate two candidates against amyotrophic lateral sclerosis, as the Japanese firm looks to build its strategic interests in muscle disease.

Research & Development BioPharmaceutical

Favorable Japan Environment Nurtures Daiichi/CTL Cell Therapy Deal

Daiichi Sankyo's recent deal for Japan rights to a cell therapy agent illustrates the ongoing corporate appetite for assets able to benefit from the country's favorable regulatory framework for such products.

BioPharmaceutical Asia Pacific

Chugai Makes Regenerative Meds Move In Attractive Japan Environment

Chugai is taking concrete steps into the burgeoning regenerative medicine sector in Japan through a new clinical and commercial alliance with a domestic venture for a therapy for knee cartilage disorders.

BioPharmaceutical Japan

Deal Watch: AbbVie Moves Into Microbiome, Synthetic Biology With Synlogic Partnership

Mylan adds more than 900 over-the-counter and generic products to its portfolio with the $9.9bn acquisition of Meda. Astellas finalizes the pursuit of Ocata which it began last November.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Inflammation
  • Ophthalmic
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Ocata Therapeutics Inc.
  • Advanced Cell Technology Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Astellas Pharma Inc.
  • Senior Management
  • Paul Wotton, PhD, Pres. & CEO
    Robert Lanza, MD, CSO
    Eddy Anglade , MD, CMO
    LeRoux Jooste, SVP, Bus. Dev. & Chief Commercial Officer
  • Contact Info
  • Astellas Institute for Regenerative Medicine
    Phone: (508) 756-1212
    33 Locke Dr.
    Marlborough, MA 01752
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register